Great Point Partners LLC grew its stake in shares of Arcellx, Inc. (NASDAQ:ACLX – Free Report) by 64.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 492,000 shares of the company’s stock after acquiring an additional 192,000 shares during the period. Arcellx accounts for approximately 5.2% of Great Point Partners LLC’s portfolio, making the stock its 6th largest holding. Great Point Partners LLC’s holdings in Arcellx were worth $27,153,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the stock. Quest Partners LLC bought a new position in shares of Arcellx in the second quarter valued at approximately $27,000. Plato Investment Management Ltd purchased a new stake in Arcellx in the 1st quarter worth approximately $51,000. National Bank of Canada FI lifted its stake in Arcellx by 50.0% in the 2nd quarter. National Bank of Canada FI now owns 1,500 shares of the company’s stock worth $80,000 after purchasing an additional 500 shares in the last quarter. Public Employees Retirement Association of Colorado bought a new position in Arcellx in the 2nd quarter valued at $178,000. Finally, Advisory Alpha LLC purchased a new position in shares of Arcellx during the 1st quarter valued at $209,000. 96.03% of the stock is owned by institutional investors.
Insider Activity at Arcellx
In other Arcellx news, CFO Michelle Gilson sold 12,877 shares of the stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $53.70, for a total value of $691,494.90. Following the completion of the sale, the chief financial officer now owns 6,915 shares in the company, valued at approximately $371,335.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Arcellx news, Director Kavita Patel sold 1,500 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $74.41, for a total transaction of $111,615.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Michelle Gilson sold 12,877 shares of the firm’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $53.70, for a total transaction of $691,494.90. Following the completion of the sale, the chief financial officer now directly owns 6,915 shares of the company’s stock, valued at $371,335.50. The disclosure for this sale can be found here. Insiders have sold a total of 129,505 shares of company stock worth $8,351,337 in the last 90 days. Company insiders own 6.24% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Stock Analysis on ACLX
Arcellx Stock Down 0.7 %
Shares of NASDAQ ACLX opened at $85.98 on Tuesday. The firm’s fifty day moving average is $66.80 and its 200 day moving average is $60.72. Arcellx, Inc. has a 52 week low of $30.88 and a 52 week high of $88.66. The company has a market cap of $4.60 billion, a price-to-earnings ratio of -83.48 and a beta of 0.23.
Arcellx (NASDAQ:ACLX – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.01. The firm had revenue of $27.38 million for the quarter, compared to analysts’ expectations of $22.04 million. Arcellx had a negative net margin of 37.23% and a negative return on equity of 12.42%. The company’s revenue was up 91.5% compared to the same quarter last year. Equities research analysts anticipate that Arcellx, Inc. will post -1.65 earnings per share for the current year.
Arcellx Company Profile
Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
See Also
- Five stocks we like better than Arcellx
- Investing in Construction Stocks
- Don’t Overlook Mosaic’s Challenges—They Might Spark Opportunity
- CD Calculator: Certificate of Deposit Calculator
- 4 Reasons GlobalFoundries Could Be a Big Winner After Recent Lows
- Basic Materials Stocks Investing
- The Average 401k Balance by Age Explained
Want to see what other hedge funds are holding ACLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcellx, Inc. (NASDAQ:ACLX – Free Report).
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.